DOCSLIB.ORG

Pocket Guide to GASTROINTESTINAL DRUGS Edited by M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pocket Guide to GASTROINTESTINAL DRUGS Edited by M Pocket Guide to GASTROINTESTINAL DRUGS Edited by M. Michael Wolfe | Robert C. Lowe Pocket Guide to Gastrointestinal Drugs Pocket Guide to Gastrointestinal Drugs Edited by M. Michael Wolfe, MD Chair, Department of Medicine MetroHealth Medical Center; Charles H. Rammelkamp, Jr. Professor of Medicine Case Western Reserve University School of Medicine Cleveland, OH, USA Robert C. Lowe, MD GI Fellowship Director Boston Medical Center; Associate Professor of Medicine Boston University School of Medicine Boston, MA, USA This edition fi rst published 2014 © 2014 by John Wiley & Sons, Ltd. Registered offi ce: John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Editorial offi ces: 9600 Garsington Road, Oxford, OX4 2DQ, UK The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offi ces, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www. wiley.com/wiley-blackwell The right of the author to be identifi ed as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher. Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought. The contents of this work are intended to further general scientifi c research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specifi c method, diagnosis, or treatment by health science practitioners for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifi cally disclaim all warranties, including without limitation any implied warranties of fi tness for a particular purpose. In view of ongoing research, equipment modifi cations, changes in governmental regulations, and the constant fl ow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/ or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom. Library of Congress Cataloging-in-Publication Data Pocket guide to gastrointestinai drugs / edited by M. Michael Wolfe, Robert C. Lowe. p. ; cm. Includes bibliographical references and index. ISBN 978-1-118-48157-8 (paperback) I. Wolfe, M. Michael, editor of compilation. II. Lowe, Robert C., 1966- editor of compilation. [DNLM: 1. Gastrointestinal Agents–therapeutic use–Handbooks. 2. Gastrointestinal Agents– pharmacology–Handbooks. 3. Gastrointestinal Diseases–drug therapy–Handbooks. QV 39] RM365 615.7’3–dc23 2013041991 A catalogue record for this book is available from the British Library. Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books. Cover image: iStock #10849434 © Mordolff Cover design by Meaden Creative Set in Palatino LT Std 9/12 pt by Aptara Inc., New Delhi, India 1 2013 Contents List of contributors, xi Preface, xvi PART I: UPPER GI TRACT 1 Prokinetic agents and antiemetics, 3 Hemangi Kale and Ronnie Fass Prokinetics, 3 Antiemetic agents, 7 Recommended reading, 14 2 Proton pump inhibitors, 15 Wanda P. Blanton and M. Michael Wolfe Introduction, 15 Mechanism of action, pharmacodynamics, kinetics, 15 Clinical use and dosing, 18 Adverse effects/safety, 27 Recommended reading, 28 3 Histamine H2-receptor antagonists, 31 Kentaro Sugano Introduction, 31 Mechanism of action, 31 Pharmacology, 33 Clinical effectiveness, 40 Adverse events, 41 Recommended reading, 42 v vi | Contents 4 Prostaglandins and other mucosal protecting agents, 44 Carlos Sostres and Angel Lanas Introduction of drug class, 44 Physicochemical properties, 45 Formulations and recommended dosages, 46 Mechanism of action, 47 Drug interactions, 48 Pharmacokinetics, 49 Clinical effectiveness, 49 Toxicity, 51 Pregnancy classes, 52 Other mucosal protecting agents, 52 Recommended reading, 54 PART II: SMALL AND LARGE INTESTINE 5 5-HT modulators and other antidiarrheal agents and cathartics, 59 Albena Halpert and Douglas Drossman Introduction, 59 5-HT modulators used in the management of GI disorders, 59 5-HT agents approved in the US for specifi c GI indications, 60 Medications used for the treatment of chronic constipation, 71 Medications used for the treatment of narcotic-induced constipation, 76 Antidiarrheal agents, 76 Conclusion, 80 Recommended reading, 80 6 5-aminosalicylates, 82 Hannah L. Miller and Francis A. Farraye Introduction, 82 Preparations, 82 Clinical use and effi cacy, 84 Pharmacology: preparations and dosing, 87 Mechanism of action, 89 Bioavailability and metabolism, 89 Contents | vii Adverse effects and toxicity, 91 Pregnancy, 93 Drug interactions (package inserts), 94 Precautions and contraindications, 94 Special considerations: effectiveness in colorectal cancer prevention, 96 Conclusion, 97 Recommended reading, 97 7 Immunosuppressive agents, 100 Lev Lichtenstein and Gerald M. Fraser Introduction, 100 Thiopurines, 100 Low-dose methotrexate (MTX), 106 Calcineurin inhibitors, 111 Recommended reading, 114 8 Biological agents, 117 Gert Van Assche Biological agents approved to treat IBD, 117 Optimal treatment strategies with anti TNF therapies in IBD, 119 Safety of biological agents in IBD, 120 Emerging biologicals, 121 Recommended reading, 121 PART III: LIVER AND PANCREAS 9 Interferons, 125 Robert C. Lowe Introduction, 125 Mechanism of action, 125 Pharmacology, 126 Clinical effectiveness, 127 Toxicity, 128 Interferon types with generic and brand names, 129 Pregnancy classes, 130 Initial interferon dosing regimens for chronic hepatitis C, 130 Recommended reading, 131 viii | Contents 10 Nucleoside analogs, 133 Uri Avissar and David P. Nunes Introduction, 133 Mechanism of action, 135 Pharmacology, 137 Clinical effectiveness, 139 Nucleoside analogs, 141 Nucleotide analogs, 146 Summary, 147 Recommended reading, 148 11 Ursodeoxycholic acid, chelating agents, and zinc in the treatment of metabolic liver diseases, 150 Andrew K. Burroughs and James S. Dooley Ursodeoxycholic acid, 150 Treatment of copper overload, 155 Recommended reading, 162 12 Agents for the treatment of portal hypertension, 165 Karen L. Krok and Andrés Cárdenas Introduction, 165 Nonselective beta-blockers (NSBB), 166 Nitrates, 169 Vasopressin analogs, 169 Somatostatin analog, 170 Midodrine, 171 Albumin, 172 Loop diuretics, 172 Aldosterone antagonist, 174 Aquaretics, 174 Disaccharides, 175 Antibiotics, 176 Recommended reading, 177 13 Pancreatic enzymes, 179 Steven J. Czinn and Samra S. Blanchard Introduction, 179 Mechanism of action, 180 Dosing and schedule of administration, 180 Contents | ix Monitoring therapy, 183 Adverse effects, 183 Recommended reading, 184 PART IV: ANTIMICROBIALS AND VACCINES 14 Antibiotics for the therapy of gastrointestinal diseases, 187 Melissa Osborn Introduction, 187 Pharmacologic properties, 187 Clinical uses, 195 Recommended reading, 202 15 Antimicrobials for parasitic diseases, 204 Joachim Richter 5-Nitroimidazoles, 204 Benzimidazoles, 206 Ivermectin, 211 Praziquantel, 212 Treatment dosages, 214 Recommended reading, 216 16 Vaccines for viral hepatitides, 219 Savio John and Raymond T. Chung Hepatitis A vaccination, 219 Hepatitis B vaccination, 222 Recommended reading, 227 17 Rotavirus and other enteric vaccinations, 229 Christopher J. Moran and Esther J. Israel Rotavirus vaccination, 229 Typhoid fever vaccination, 232 Recommended reading, 233 PART V: NUTRITION AND PROBIOTICS 18 Parenteral and enteral nutrition feeding formulas, 237 Dominic N. Reeds and Beth Taylor Introduction, 237 Indications for nutrition support, 237 Energy and macronutrient requirements, 237 x | Contents Protein, 238 Carbohydrate, 239 Lipids, 239 Enteral liquid feeding formulations, 239 Disease-specifi c formulas, 244 Selection of an appropriate
Load more

Recommended publications
  • Granisetron "Vianex"
    EU‐RISK MANAGEMENT PLAN GRANISETRON VIANEX® 1 MG/ML, SOLUTION FOR INJECTION/ INFUSION precautionary measure, breast‐feeding should not be advised during treatment with Granisetron “Vianex”. Legal Status: Prescription only product. VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Nausea and vomiting associated with chemotherapy and radiotheraphy: One of the most distressing symptoms for patients undergoing both surgery and chemotherapy is nausea and vomiting. These symptoms have a significant impact on quality of life and can lead to malnutrition, inability to respond to treatment and an increased length of hospitalization. Emesis is more commonly associated with chemotherapeutic agents; however, radiation‐induced nausea and vomiting (RINV) can affect a significant proportion of patients, depending on the treated area, dose fractionation, and volume of radiotherapy. The relative risk for developing nausea and vomiting with chemotherapy ranges from 30 to 90% and is dependent upon the chemotherapeutic agent used. Relative risk for nausea and vomiting with radiation therapy is approximately 40%.2,3,4,5 Post‐operative nausea and vomiting Postoperative nausea and vomiting (PONV) is a major source of patient dissatisfaction and is the leading cause of discharge delays and unanticipated postsurgical hospital admissions. In the absence of pharmacological treatment, the rate of PONV is approximately 30% in general population, and can be as high as 70% in patients at highest risk. Several risk factors as surgery type, female gender, non‐smoker status, history of postoperative nausea and vomiting or motion sickness and post‐operative opioid use have been acknowledged. Additionally, post‐ operative vomiting (POV) occurs twice as frequently in children as in adults, increasing until puberty and then decreasing to adult incidence rates.
    [Show full text]
  • Therapeutic Class Overview Irritable Bowel Syndrome Agents
    Therapeutic Class Overview Irritable Bowel Syndrome Agents Therapeutic Class Overview/Summary: This review will focus on agents used for the treatment of Irritable Bowel Syndrome (IBS).1-5 IBS is a gastrointestinal syndrome characterized primarily by non-specific chronic abdominal pain, usually described as a cramp-like sensation, and abnormal bowel habits, either constipation or diarrhea, in which there is no organic cause. Other common gastrointestinal symptoms may include gastroesophageal reflux, dysphagia, early satiety, intermittent dyspepsia and nausea. Patients may also experience a wide range of non-gastrointestinal symptoms. Some notable examples include sexual dysfunction, dysmenorrhea, dyspareunia, increased urinary frequency/urgency and fibromyalgia-like symptoms.6 IBS is defined by one of four subtypes. IBS with constipation (IBS-C) is the presence of hard or lumpy stools with ≥25% of bowel movements and loose or watery stools with <25% of bowel movements. When IBS is associated with diarrhea (IBS-D) loose or watery stools are present with ≥25% of bowel movements and hard or lumpy stools are present with <25% of bowel movements. Mixed IBS (IBS-M) is defined as the presence of hard or lumpy stools with ≥25% and loose or water stools with ≥25% of bowel movements. Final subtype, or unsubtyped, is all other cases of IBS that do not fall into the other classes. Pharmacological therapy for IBS depends on subtype.7 While several over-the-counter or off-label prescription agents are used for the treatment of IBS, there are currently only two agents approved by the Food and Drug Administration (FDA) for the treatment of IBS-C and three agents approved by the FDA for IBS-D.
    [Show full text]
  • Novel Formulations for Treatment of Migraine
    (19) TZZ _T (11) EP 2 756 756 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.07.2014 Bulletin 2014/30 A01N 43/42 (2006.01) A61K 31/44 (2006.01) (21) Application number: 14165112.5 (22) Date of filing: 24.04.2009 (84) Designated Contracting States: • Turanin, John AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Emeryville, CA California 94608 (US) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Hawley, Roger PT RO SE SI SK TR Emeryville, CA California 94608 (US) • Schuster, Jeffrey, A. (30) Priority: 28.04.2008 US 48463 Bolinas, CA California 94924 (US) (62) Document number(s) of the earlier application(s) in (74) Representative: Duxbury, Stephen et al accordance with Art. 76 EPC: Arnold & Siedsma 09739139.5 / 2 273 880 Pettenkoferstrasse 37 80336 München (DE) (71) Applicant: Zogenix, Inc. Emeryville CA 94608 (US) Remarks: This application was filed on 17-04-2014 as a (72) Inventors: divisional application to the application mentioned • Farr, Stephen J. under INID code 62. Orinda, CA California 94563 (US) (54) Novel formulations for treatment of migraine (57) Systems and methods are described for treating Systems that are self contained, portable, prefilled, and un-met medical needs in migraine and related conditions simple to self administer at the onset of a migraine attack such as cluster headache. Included are treatments that are disclosed, and preferably include a needle-free in- are both rapid onset and long acting, which include sus- jector and a high viscosity formulation, to eliminate such tained release formulations, and combination products, issues as fear of self administration with needles, and Also included are treatments for multiple symptoms of needle stick and cross contamination.
    [Show full text]
  • 1Hol=C2 Light Water (C2 > C1) Patent Application Publication May 1, 2008 US 2008/O103092 A1 5 (1H2O=C2
    US 20080 103092A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0103092 A1 Pomytkin et al. (43) Pub. Date: May 1, 2008 (54) METHODS FOR INTRADERMAL, Publication Classification TRANSIDERMAL, ORTRANSMUCOSAL DELIVERY OF BIOLOGICALLY ACTIVE (51) Int. Cl. SUBSTANCES A6II 47/02 (2006.01) A6II 38/02 (2006.01) (76) Inventors: Igor Anatolievich Pomytkin, Moscow A6IR 48/00 (2006.01) (RU); Sergey Pavlovich Soloviev, (52) U.S. Cl. .................................... 514/8: 514/2: 514/769 Moscow (RU) (57) ABSTRACT Correspondence Address: NOTARO AND MICHALOS This invention relates to method for intradermal, transdermal 1OO DUTCH HILL ROAD or transmucosal delivering a biologically active Substance to a mammal in need thereof, which method comprises a step of SUTE 110 co-administering to said mammal with the biologically active ORANGEBURG, NY 10962-2100 (US) Substance an effective amount of an absorption enhancer, which is water comprising from about 99.760 to about 10 (21) Appl. No.: 11/817,919 99.999% of light isotopologue H, 0 and up to 100% of residual isotopologues H, '70, H., '80, HH'0, HH'70, (22) PCT Filed: Mar. 11, 2005 'HH'0, H, O, H, '70, and H 0. Such biologically (86) PCT NO.: PCT/RUOS/OO108 active substance is selected from the group consisting of drugs, physiologically active peptides, physiologically active S371(c)(1), proteins, glycoproteins, nucleic acid, nutrients, vitamins, and (2), (4) Date: Nov. 15, 2007 minerals. 5 1Hol=C2 Light Water (C2 > C1) Patent Application Publication May 1, 2008 US 2008/O103092 A1 5 (1H2O=C2 Light Water (C2 > C1) Licuid US 2008/O 103092 A1 May 1, 2008 METHODS FOR INTRADERMAL, TRANSDERMAL wherein the level of light water isotopologue 'H'Ois about ORTRANSMUCOSAL DELIVERY OF 99.7317% (Vienna Standard Mean Ocean Water, VSMOW), BIOLOGICALLY ACTIVE SUBSTANCES and wherein total level of all eight heavy isotopologues com prising at least one heavy isotopes H, O, and 'O is about TECHNICAL FIELD 0.2683% (e.g.
    [Show full text]
  • Antihypotensive Agent Disrupts the Immune System in Sepsis 12 June 2020
    Antihypotensive agent disrupts the immune system in sepsis 12 June 2020 Patients who go into septic shock are treated with with endotoxin, a bacterial cell-wall component. If the antihypotensive agent norepinephrine. mice were administered norepinephrine, their Researchers from Radboud University Medical immune response was strongly suppressed." Center published results in today's American Journal of Respiratory and Critical Care Medicine Furthermore, in mice with an actual bacterial revealing that its use is not without drawbacks: The infection, infusion of norepinephrine led to drug disrupts the immune system and increases increased bacterial growth in the spleen, liver, and susceptibility to infections. This may have negative blood, again indicating a weakened immune consequences for patients. Research into system. "We also studied the effect of vasopressin, alternatives is therefore justified. an alternative antihypotensive agent, on white blood cells and mice," Stolk says. "Interestingly, in Sepsis is a life-threatening inflammatory response contrast to norepinephrine, this drug has no effects spreading throughout the body due to an infection. on the immune system or defense against One in four patients with sepsis succumbs to it, infections." and it is the No. 1 cause of death around the globe. As such, sepsis was recently designated as Healthy volunteers a global health priority by the World Health Organization (WHO). Patients with sepsis have a "Next, we wanted to know whether the effects of severely dysregulated immune system, which norepinephrine also apply to humans," said Matthijs impairs clearance of the infection and leaves the Kox, head of the study. "We infused either body susceptible to new infections with an norepinephrine, vasopressin, or a placebo in three increased risk of death.
    [Show full text]
  • 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: the Iceberg Still Lies Beneath the Surface
    1521-0081/71/3/383–412$35.00 https://doi.org/10.1124/pr.118.015487 PHARMACOLOGICAL REVIEWS Pharmacol Rev 71:383–412, July 2019 Copyright © 2019 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: JEFFREY M. WITKIN 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface Gohar Fakhfouri,1 Reza Rahimian,1 Jonas Dyhrfjeld-Johnsen, Mohammad Reza Zirak, and Jean-Martin Beaulieu Department of Psychiatry and Neuroscience, Faculty of Medicine, CERVO Brain Research Centre, Laval University, Quebec, Quebec, Canada (G.F., R.R.); Sensorion SA, Montpellier, France (J.D.-J.); Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran (M.R.Z.); and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada (J.-M.B.) Abstract. ....................................................................................384 I. Introduction. ..............................................................................384 II. 5-HT3 Receptor Structure, Distribution, and Ligands.........................................384 A. 5-HT3 Receptor Agonists .................................................................385 B. 5-HT3 Receptor Antagonists. ............................................................385 Downloaded from 1. 5-HT3 Receptor Competitive Antagonists..............................................385 2. 5-HT3 Receptor
    [Show full text]
  • Gastroparesis: 2014
    GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #1 Richard W. McCallum, MD, FACP, FRACP (Aust), FACG Status of Pharmacologic Management of Gastroparesis: 2014 Richard W. McCallum Joseph Sunny, Jr. Gastroparesis is characterized by delayed gastric emptying without mechanical obstruction of the gastric outlet or small intestine. The main etiologies are diabetes, idiopathic and post- gastric and esophageal surgical settings. The management of gastroparesis is challenging due to a limited number of medications and patients often have symptoms, which are refractory to available medications. This article reviews current treatment options for gastroparesis including adverse events and limitations as well as future directions in pharmacologic research. INTRODUCTION astroparesis is a syndrome characterized by documented gastroparesis are increasing.2 Physicians delayed emptying of gastric contents without have both medical and surgical approaches for these Gmechanical obstruction of the stomach, pylorus or patients (See Figure 1). Medical therapy includes both small bowel. Patients can present with nausea, vomiting, prokinetics and antiemetics (See Table 1 and Table 2). postprandial fullness, early satiety, pressure, fullness The gastroparesis population will grow as diabetes and abdominal distension. In addition, abdominal pain increases and new therapies will be required. What located in the epigastrium, and distinguished from the do we know about the size of the gastroparetic term discomfort, is increasingly being recognized population? According to a study from the Mayo Clinic as an important symptom. The main etiologies of group surveying Olmsted County in Minnesota, the gastroparesis are diabetes, idiopathic, and post gastric risk of gastroparesis in Type 1 diabetes mellitus was and esophageal surgeries.1 Hospitalizations from significantly greater than for Type 2.
    [Show full text]
  • 8-GI Drugs Final
    Gastrointestinal Drugs Subcommittee: Prozialeck, Walter (Chair) [email protected] Escher, Emanuel [email protected] Garrison, James C. [email protected] Henry, Matthew, [email protected] Weber, Donna R [email protected] Recommended Curriculum Equivalent: 1.5 h Acid Reducers and Drugs for the Treatment of Peptic Ulcer Disease Proton pump inhibitors First generation Second generation OMEPRAZOLE ESOMEPRAZOLE LANSOPRAZOLE PANTOPRAZOLE RABEPRAZOLE Learning Objectives Physiology and pathophysiology Describe the synthesis and mechanism of H+ secretion by the parietal cells Mechanism of action Describe the mechanism of action of proton pump inhibitors and why they are selective for the parietal cell proton pump. Actions on organ systems Describe the pharmacological effects of the drugs on gastric function. Are there effects on other organ systems? Pharmacokinetics Describe the pharmacokinetics of proton pump inhibitors? Are there significant differences among the different drugs in this class? Adverse effects, drug interactions and contraindications Describe the principal adverse effects of proton pump inhibitors. Describe the clinically important drug interactions of proton pump inhibitors. Describe the principal contraindications of proton pump inhibitors. Therapeutic uses Describe the current therapeutic uses of proton pump inhibitors. 1 Clinical Pharmacology Omeprazole is perceived to be the most potent of this drug class in inhibiting CYP2C19 activity and is proposed to have potential drug interactions with other drugs metabolized by this P450 isoform. Concern has been raised about potential inhibition of clopidogrel activation in patients taking both drugs concurrently. Current consensus is that in such patients clopidogrel with pantoprazole may be a safer choice to reduce the probability of a drug interaction involving CYP2C19.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Midodrine Hydrochloride Tablets, USP Rx Only
    MIDODRINE HCL- midodrine hydrochloride tablet Eon Labs, Inc. ---------- Midodrine Hydrochloride Tablets, USP Rx Only WARNING Because midodrine hydrochloride tablets can cause marked elevation of supine blood pressure, it should be used in patients whose lives are considerably impaired despite standard clinical care. The indication for use of midodrine hydrochloride tablets in the treatment of symptomatic orthostatic hypotension is based primarily on a change in a surrogate marker of effectiveness, an increase in systolic blood pressure measured one minute after standing, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of midodrine hydrochloride tablets, principally improved ability to carry out activities of daily living, have not been verified. DESCRIPTION Midodrine hydrochloride is a vasopressor/antihypotensive agent. Midodrine hydrochloride is an odorless, white, crystalline powder, soluble in water and sparingly soluble in methanol having a pKa of 7.8 (0.3% aqueous solution), a pH of 3.5 to 5.5 (5% aqueous solution) and a melting range of 200°C to 203°C. It is chemically described as: (1) Acetamide, 2-amino-N-[2-(2,5-dimethoxyphenyl)-2- hydroxyethyl]-monohydrochloride, (±)-; or (2) (±)-2-amino-N-(ß-hydroxy-2,5- dimethoxyphenethyl)acetamide monohydrochloride. Midodrine hydrochloride’s molecular formula is C12H18N2O4HCl, its molecular weight is 290.7 and its structural formula is: Each tablet for oral administration contains 2.5 mg, 5 mg or 10 mg of midodrine hydrochloride and the following inactive ingredients: pregelatinized starch (corn starch), microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate. In addition, the 5 mg tablets contain FD&C yellow No.
    [Show full text]
  • CISAPRIDE (Veterinary—Systemic)
    CISAPRIDE (Veterinary—Systemic) There are no human- or veterinary-labeled commercial ELUS,CANDelayed gastric emptying (treatment)EL; or cisapride products in the United States or Canada. ELUS,CANSmall bowel motility disorders (treatment)EL— Although no feline studies are available, the Category: Gastrointestinal emptying adjunct; documented effects of cisapride in healthy dogs and peristaltic stimulant. other animals suggest it may have efficacy in disorders that benefit from stimulation of gastric, Indications small intestinal, or colonic motility and from Note: Cisapride is not specifically approved for shortened transit time in cats (Evidence rating: B- {R-2; 4-7; 21-24} veterinary use. In other USP information 2). monographs, the ELUS and ELCAN designations refer to uses that are not included in U.S. and Canadian Dogs product labeling; however, in this monograph Potentially effective they reflect the lack of commercial product ELUS,CANGastroesophageal reflux (treatment)EL; availability in the countries indicated. See also the ELUS,CANDelayed gastric emptying (treatment)EL; Regulatory Considerations section below in this ELUS,CANSmall bowel motility disorders (treatment)EL; or monograph. US,CAN EL Colonic motility disorders (treatment)EL — Classification as Accepted, Potentially effective, Although no studies of clinical disease states are or Unaccepted is an evaluation of reasonable use available, studies of the effects of cisapride in that considers clinical circumstances, including healthy dogs suggest it may have efficacy in the availability of other therapies. The quality of disorders that benefit from stimulation of gastric, evidence reviewed for an indication is shown by small intestinal, or colonic motility and from the evidence rating. shortened transit time (Evidence rating: B-2 [table 1][table 2][table3]).{R-4-7; 17; 21-24} Cats Accepted Note: There is no evidence that cisapride is effective in ELUS,CAN EL Constipation, chronic (treatment) ; or the treatment of megaesophagus in dogs.
    [Show full text]
  • Investigating the Pharmacology of Novel 5-HT3 Receptor Ligands; with the Potential to Treat Neuropsychiatric and Gastrointestinal Disorders
    Investigating the pharmacology of novel 5-HT3 receptor ligands; with the potential to treat neuropsychiatric and gastrointestinal disorders by Alexander Roberts A thesis submitted to the University of Birmingham for the Degree of Doctor of Philosophy Institute of Clinical Sciences College of Medical and Dental Sciences University of Birmingham February 2020 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Abstract The 5-hydroxytryptamine (5-HT; serotonin) 5-HT3 receptor is an excitatory ligand- gated ion channel expressed in for example the brain and the gastrointestinal tract. Two major subtypes of the receptor have been studied in the most detail; the homomeric 5-HT3A receptor and the heteromeric 5-HT3AB receptor. 5-HT3 receptor antagonists are used clinically to treat chemotherapy induced and post-operative nausea and vomiting, and demonstrate symptomatic relief in diarrhoea-predominant irritable bowel syndrome (IBS-d); but unfortunately, these medications cause adverse effects such as constipation or rarely ischemic colitis in the latter condition. This study has characterised the pharmacology of two structurally distinct 5-HT3 receptor partial agonists (vortioxetine and CSTI-300); and identified the unique binding properties of the cryptic orthosteric modulator 5-chloroindole (Cl-indole) for the human (h) 5-HT3 receptor.
    [Show full text]